<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00898378</url>
  </required_header>
  <id_info>
    <org_study_id>0808-24; IUCRO-0221</org_study_id>
    <secondary_id>P30CA082709</secondary_id>
    <secondary_id>IUCRO-0221</secondary_id>
    <nct_id>NCT00898378</nct_id>
  </id_info>
  <brief_title>Study of Biomarkers in Blood &amp; Tissue Samples From Patients With Colorectal Cancer or Polyps &amp; Patients Without Polyps</brief_title>
  <official_title>Cancer Care Engineering of Colorectal Cancer - OMICs Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer,
      patients with colorectal polyps and from patients without polyps may help doctors learn more
      about changes that occur in DNA and identify biomarkers related to cancer.

      PURPOSE: This research study is looking at biomarkers in blood and tissue samples from
      patients with colorectal cancer or colorectal polyps and from patients without polyps
      (healthy volunteers).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Perform metabolomic, lipidomic, glycoproteomic, proteomic, and genomic (OMIC) profiling
           using blood and tissue samples from patients with colorectal cancer (CRC) or colorectal
           adenomatous polyps and from patients without polyps.

        -  Create an OMIC profile to predict the risk of CRC based on differences observed between
           patients with CRC, patients with colorectal adenomatous polyps, and patients without
           polyps.

      Secondary

        -  Create an OMIC profile to predict response and toxicity to specific chemotherapies,
           biological therapies, and radiotherapy for CRC.

        -  Utilize a novel knowledge discovery tool (BioMap) based on literature mining and, in the
           future, utilize the results of the OMIC analyses to identify interactive molecular
           pathways that underlie the development and progression of CRC.

      OUTLINE: Patients with locally advanced or metastatic colorectal cancer are stratified
      according to treatment (first-line chemotherapy with fluorouracil [5-FU]/oxaliplatin or
      5-FU/irinotecan vs second- or third-line chemotherapy with irinotecan only vs biological
      therapy with bevacizumab vs biological therapy with cetuximab vs radiotherapy).

      Blood and tissue samples are collected periodically for laboratory studies. Samples are
      analyzed for metabolomics by nuclear magnetic resonance, gas chromatography, liquid
      chromatography, and mass spectrometry; lipidomics, proteomics, and glycoproteomics by liquid
      chromatography and mass spectrometry; and genomics (single nucleotide polymorphism
      biomarkers) by PCR. Vitamin D status is also assessed.

      Patients complete diet-history and lifestyle questionnaires at baseline and once a year for 2
      years. Healthy volunteers complete these questionnaires only at baseline.

      After completion of study, patients are followed every 3 months for 2 years, every 6 months
      for 3 years, and then annually thereafter. Healthy volunteers are not followed after study
      completion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolomic, lipidomic, glycoproteomic, proteomic, and genomic (OMIC) profiling</measure>
    <time_frame>End of Study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Creation of an OMIC profile to predict the risk of colorectal cancer (CRC)</measure>
    <time_frame>End of Study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Creation of an OMIC profile to predict response and toxicity to specific therapies for CRC</measure>
    <time_frame>End of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of interactive molecular pathways that underlie the development and progression of CRC</measure>
    <time_frame>End of Study</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">551</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Healthy, no Evidence of Disease</condition>
  <condition>Precancerous Condition</condition>
  <arm_group>
    <arm_group_label>Colorectal Cancer Patients</arm_group_label>
    <description>Patients with stages I/II, III and IV colorectal cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colorectal Polyps Patients</arm_group_label>
    <description>Patients with adenomatous polyp(s) after colonoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>No abnormalities after colonoscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
    <description>gene expression analysis</description>
    <arm_group_label>Colorectal Cancer Patients</arm_group_label>
    <arm_group_label>Colorectal Polyps Patients</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <description>polymerase chain reaction</description>
    <arm_group_label>Colorectal Cancer Patients</arm_group_label>
    <arm_group_label>Colorectal Polyps Patients</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
    <description>polymorphism analysis</description>
    <arm_group_label>Colorectal Cancer Patients</arm_group_label>
    <arm_group_label>Colorectal Polyps Patients</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
    <description>protein expression analysis</description>
    <arm_group_label>Colorectal Cancer Patients</arm_group_label>
    <arm_group_label>Colorectal Polyps Patients</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>proteomic profiling</intervention_name>
    <description>proteomic profiling</description>
    <arm_group_label>Colorectal Cancer Patients</arm_group_label>
    <arm_group_label>Colorectal Polyps Patients</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>gas chromatography</intervention_name>
    <description>gas chromatography</description>
    <arm_group_label>Colorectal Cancer Patients</arm_group_label>
    <arm_group_label>Colorectal Polyps Patients</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>laboratory biomarker analysis</description>
    <arm_group_label>Colorectal Cancer Patients</arm_group_label>
    <arm_group_label>Colorectal Polyps Patients</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>liquid chromatography</intervention_name>
    <description>liquid chromatography</description>
    <arm_group_label>Colorectal Cancer Patients</arm_group_label>
    <arm_group_label>Colorectal Polyps Patients</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mass spectrometry</intervention_name>
    <description>mass spectrometry</description>
    <arm_group_label>Colorectal Cancer Patients</arm_group_label>
    <arm_group_label>Colorectal Polyps Patients</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <description>questionnaire administration</description>
    <arm_group_label>Colorectal Cancer Patients</arm_group_label>
    <arm_group_label>Colorectal Polyps Patients</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biospecimens will be analyzed to study metabolimics, lipidomics, genomics, glycoproteomics,
      global proteomics and Vitamin D status.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be recruited via oncology, gastroenterology and surgical oncology clinics at
        Indiana University Medical Center. Healthy controls will be subjects without any
        abnormalities after a colonoscopy. Subjects with polyps will be those whose colonoscopy
        identifies adenomatous polyps (informed consent will be signed first and samples will be
        collected; after colonoscopy the samples will be identified as &quot;healthy&quot; or &quot;polyps&quot;).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Meets 1 of the following criteria:

               -  Diagnosis of one of the following:

                    -  Stage I or II colorectal cancer (CRC)*

                         -  Planning to undergo surgery only

                    -  Stage III CRC*

                         -  Planning to undergo surgery followed by adjuvant chemotherapy with or
                            without neoadjuvant chemoradiotherapy

                    -  Stage IV CRC

                         -  Planning to undergo chemotherapy and biologic therapy (bevacizumab,
                            cetuximab, or panitumumab)

                    -  Colorectal adenomatous polyps

                         -  Planning to undergo colonoscopy

               -  Healthy volunteer

                    -  Planning to undergo colonoscopy NOTE: *Patients with previously resected
                       stage II or III CRC are eligible provided they undergo blood sample
                       collection prior to starting chemotherapy

        PATIENT CHARACTERISTICS:

          -  Not pregnant

          -  Able to undergo an 8-hour overnight fast prior to metabolomic testing

          -  Able to attend follow-up or treatment visits for up to 24 months for collection of
             blood samples

          -  No prior or concurrent invasive cancer other than CRC (for patients with CRC)

          -  No prior invasive cancer and no first-degree relative with a known history of CRC (for
             healthy volunteers and patients with colorectal polyps)

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick J Loehrer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University Melvin and Bren Simon Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5289</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>September 17, 2014</last_update_submitted>
  <last_update_submitted_qc>September 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy, no evidence of disease</keyword>
  <keyword>stage I colon cancer</keyword>
  <keyword>stage II colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage I rectal cancer</keyword>
  <keyword>stage II rectal cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>adenomatous polyp</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

